Legacy Capital Wealth Partners LLC Takes Position in Cencora, Inc. (NYSE:COR)

Legacy Capital Wealth Partners LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,033 shares of the company's stock, valued at approximately $908,000.

Several other hedge funds have also recently bought and sold shares of COR. Lake Street Advisors Group LLC grew its stake in shares of Cencora by 1.3% in the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock worth $769,000 after purchasing an additional 43 shares during the last quarter. Financial Advocates Investment Management grew its stake in shares of Cencora by 4.7% in the second quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock worth $220,000 after purchasing an additional 44 shares during the last quarter. Checchi Capital Advisers LLC grew its stake in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock worth $499,000 after purchasing an additional 48 shares during the last quarter. J.W. Cole Advisors Inc. lifted its holdings in Cencora by 1.3% in the third quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company's stock valued at $826,000 after buying an additional 48 shares during the period. Finally, Valeo Financial Advisors LLC lifted its holdings in Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock valued at $353,000 after buying an additional 51 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 15.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on COR shares. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. UBS Group upped their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday. StockNews.com lowered shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Finally, Bank of America reiterated a "neutral" rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $271.20.

Cencora Stock Up 0.3 %

Shares of COR traded up $0.65 on Friday, reaching $248.41. The company's stock had a trading volume of 1,376,073 shares, compared to its average volume of 1,341,350. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a twelve month low of $191.11 and a twelve month high of $251.00. The stock has a market capitalization of $48.95 billion, a PE ratio of 33.08, a PEG ratio of 1.55 and a beta of 0.44. The firm has a fifty day moving average of $231.95 and a 200-day moving average of $230.74.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.89%. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. Cencora's dividend payout ratio is presently 27.16%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.